Doaa Ali Abdelmonsif1,2, Ahmed S Sultan3, Wessam F El-Hadidy4, Dina Mohamed Abdallah5. 1. Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Alexandria, Egypt. doaa.elmonsif@alexmed.edu.eg. 2. Molecular Biology and Nanomedicine Laboratories, Centre of Excellence for Regenerative Medicine Research and Applications, Faculty of Medicine, Alexandria University, Alexandria, Egypt. doaa.elmonsif@alexmed.edu.eg. 3. Department of Biochemistry, Faculty of Science, Alexandria University, Alexandria, Egypt. 4. Department of Pharmacology and Experimental Therapeutics, Medical Research Institute, Alexandria University, Alexandria, Egypt. 5. Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is an expanding health problem with a great impact on morbidity and mortality, both in Egypt and worldwide. Recently, metformin and aspirin showed a potential anticancer effect on HCC, although the mechanism of this effect is not fully elucidated. OBJECTIVE: The current work aimed to investigate the possibility of targeting AMP-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), and β-catenin proteins through combined metformin/aspirin treatment in the HepG2 cell line, and to explore such molecular targets in Egyptian HCC patients. MATERIALS AND METHODS: HepG2 cells were exposed to increasing concentrations of metformin, aspirin and combined treatment, and an MTT assay was performed to determine half maximal inhibitory concentration (IC50). Caspase-3 activity, cell cycle analysis, and protein expression of AMPK, phosphorylated AMPK (pAMPK) and mTOR proteins were assessed. Furthermore, the expression and localization of β-catenin protein was assessed by immunocytochemistry, and protein expression of pAMPK, mTOR and β-catenin was assessed in Egyptian HCC and cirrhotic tissue specimens. RESULTS: Metformin/aspirin combined treatment had a synergistic effect on cell cycle arrest at the G2/M phase and apoptosis induction in a caspase-dependent manner via downregulation of pAMPK and mTOR protein expression. Additionally, metformin/aspirin combined treatment enhanced cell-cell membrane localization of β-catenin expression in HepG2 cells, which might inhibit the metastatic potential of HepG2 cells. In Egyptian HCC specimens, pAMPK, mTOR and β-catenin proteins showed a significant increased expression compared with cirrhotic controls. CONCLUSIONS: Targeting AMPK, mTOR and β-catenin by combined metformin/aspirin treatment could be a promising therapeutic strategy for Egyptian HCC patients, and possibly other HCC patients.
BACKGROUND:Hepatocellular carcinoma (HCC) is an expanding health problem with a great impact on morbidity and mortality, both in Egypt and worldwide. Recently, metformin and aspirin showed a potential anticancer effect on HCC, although the mechanism of this effect is not fully elucidated. OBJECTIVE: The current work aimed to investigate the possibility of targeting AMP-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), and β-catenin proteins through combined metformin/aspirin treatment in the HepG2 cell line, and to explore such molecular targets in Egyptian HCC patients. MATERIALS AND METHODS: HepG2 cells were exposed to increasing concentrations of metformin, aspirin and combined treatment, and an MTT assay was performed to determine half maximal inhibitory concentration (IC50). Caspase-3 activity, cell cycle analysis, and protein expression of AMPK, phosphorylated AMPK (pAMPK) and mTOR proteins were assessed. Furthermore, the expression and localization of β-catenin protein was assessed by immunocytochemistry, and protein expression of pAMPK, mTOR and β-catenin was assessed in Egyptian HCC and cirrhotic tissue specimens. RESULTS:Metformin/aspirin combined treatment had a synergistic effect on cell cycle arrest at the G2/M phase and apoptosis induction in a caspase-dependent manner via downregulation of pAMPK and mTOR protein expression. Additionally, metformin/aspirin combined treatment enhanced cell-cell membrane localization of β-catenin expression in HepG2 cells, which might inhibit the metastatic potential of HepG2 cells. In Egyptian HCC specimens, pAMPK, mTOR and β-catenin proteins showed a significant increased expression compared with cirrhotic controls. CONCLUSIONS: Targeting AMPK, mTOR and β-catenin by combined metformin/aspirin treatment could be a promising therapeutic strategy for Egyptian HCC patients, and possibly other HCC patients.
Authors: Andrew J O'Brien; Linda A Villani; Lindsay A Broadfield; Vanessa P Houde; Sandra Galic; Giovanni Blandino; Bruce E Kemp; Theodoros Tsakiridis; Paola Muti; Gregory R Steinberg Journal: Biochem J Date: 2015-05-05 Impact factor: 3.857
Authors: Isaam Ben Sahra; Claire Regazzetti; Guillaume Robert; Kathiane Laurent; Yannick Le Marchand-Brustel; Patrick Auberger; Jean-François Tanti; Sophie Giorgetti-Peraldi; Frédéric Bost Journal: Cancer Res Date: 2011-05-03 Impact factor: 12.701
Authors: Wolfgang Sieghart; Thorsten Fuereder; Katharina Schmid; Daniel Cejka; Johannes Werzowa; Fritz Wrba; Xiaowei Wang; Diego Gruber; Susanne Rasoul-Rockenschaub; Markus Peck-Radosavljevic; Volker Wacheck Journal: Transplantation Date: 2007-02-27 Impact factor: 4.939
Authors: Farhat V N Din; Asta Valanciute; Vanessa P Houde; Daria Zibrova; Kevin A Green; Kei Sakamoto; Dario R Alessi; Malcolm G Dunlop Journal: Gastroenterology Date: 2012-03-06 Impact factor: 22.682
Authors: Maria Eduarda Azambuja Amaral; Laura Roesler Nery; Carlos Eduardo Leite; Walter Filgueira de Azevedo Junior; Maria Martha Campos Journal: Invest New Drugs Date: 2018-02-02 Impact factor: 3.850
Authors: Heba R Al Refaey; Al-Sayeda A Newairy; Mayssaa M Wahby; Chris Albanese; Mohamed Elkewedi; Muhammad Umer Choudhry; Ahmed S Sultan Journal: Biol Res Date: 2021-05-28 Impact factor: 5.612